BioSpace News Archive

Advancing the 150-year-old practice of pathology to improve patient care

Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the last visit of the last patient enrolled in the Phase II/III REVERSE-IT study on the active substance TOTUM•63.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced financial results for the fourth quarter and full year 2022 and provided an update on recent corporate developments.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023.

AngioDynamics, Inc. (NASDAQ: ANGO) today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March 30, 2023.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022.

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022.

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of a reasonable best efforts public offering of 3,503,665 American Depositary Shares at a public offering price of $1.50 per ADS.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, issued a statement confirming that it does not hold cash deposits or securities at Silicon Valley Bank.

Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis.